Clinical Trials Sponsored by Santeon

Total 533 results

Santen Inc.
MacuSight, Inc.

Terminated

Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration

Age-related Macular Degeneration | Choroidal Neovascularization

United States
Santen Inc.
MacuSight, Inc.

Terminated

Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis® in Patients With Age-Related Macular Degeneration (EMERALD)

Age-Related Macular Degeneration | Choroidal Neovascularization

United States
Santen Pharmaceutical Co., Ltd.

Completed

Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-Angle Glaucoma

Japan
Synthon BV

Completed

Efficacy and Safety of GTR in Comparison to Copaxone® (GATE)

Multiple Sclerosis

United States, Belarus, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Estonia, Georgia, Germany, Italy, Mexico, Moldova, Republic of, Poland, Romania, Russian Federation, Serbia, South Africa, Ukraine, United Kingdom
Santen Pharmaceutical Co., Ltd.

Recruiting

A Long Term Study of STN1012600 in Subjects With Open Angle Glaucoma or Ocular Hypertension

Open Angle Glaucoma, Ocular Hypertension

Japan
Santen Pharmaceutical Co., Ltd.

Completed

A Study Assessing the Efficacy and Safety of DE-127 Ophthalmic Solution in Subjects With Mild or Moderate Myopia (APPLE)

Myopia

Singapore
Santen Pharmaceutical Co., Ltd.

Completed

A Study Assessing Safety and Efficacy of MD-15 Intraocular Lens in Patients With Aphakic Eye After Cataract Surgery

Cataract

Japan
Santen Pharmaceutical Co., Ltd.

Completed

A Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension -AYAME Study-

Primary Open Angle Glaucoma | Ocular Hypertension

Japan
Santen Pharmaceutical Co., Ltd.

Completed

Study of Methacholine Chloride Inhalation Challenge in Children With Bronchial Asthma

Asthma

Japan
Santen Pharmaceutical Co., Ltd.

Completed

DE-111 Against Timolol Ophthalmic Solution 0.5%

Ocular Hypertension | Open Angle Glaucoma

Japan
Santen Pharmaceutical Co., Ltd.

Completed

Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis

Allergic Conjunctivitis

Japan
Santen Inc.
MacuSight, Inc.

Completed

Dose Ranging Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Diabetic Macular Edema

Diabetic Macular Edema

United States
Santen Pharmaceutical Co., Ltd.

Completed

Study of DE-089 Ophthalmic Solution in Patients With Dry Eye

Dry Eye

Singapore, China
Santen Inc.
MacuSight, Inc.

Completed

Safety and Tolerability of MS-R001 in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy

Diabetic Retinopathy | Diabetic Macular Edema

United States
Santen Inc.
Vistakon Pharmaceuticals

Terminated

Ocular Penetration of 1.5% Levofloxacin and 0.5% Moxifloxacin During Corneal Transplant Surgery

Corneal Transplantation

United States
Santen Pharmaceutical Co., Ltd.

Completed

To Investigate the Safety and Efficacy of DE-104 Ophthalmic Solution to Treat Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-Angle Glaucoma

Japan
Santen Inc.
ActualEyes Inc.

Recruiting

A Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared With Vehicle in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD) (PHANTOM)

Fuchs Endothelial Corneal Dystrophy

United States
Santen Pharmaceutical Co., Ltd.

Completed

A Phase III Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Compared With Latanoprost Ophthalmic Solution in Subjects With OAG or OHT

Open Angle Glaucoma or Ocular Hypertension

Singapore
Santen Pharmaceutical Co., Ltd.

Completed

Pharmacokinetic Study of STN1012600 Ophthalmic Solution in Healthy Adult Males Volunteers

Healthy Adult Males Volunteers

Japan
Santen Pharmaceutical Co., Ltd.

Completed

A Study of DE-111A on the Treatment of Open Angle Glaucoma or Ocular Hypertension

Open-angle Glaucoma, Ocular Hypertension

China
Santen Pharmaceutical Co., Ltd.

Completed

Assessing Safety and Efficacy of DE-089 Ophthalmic Solution in Patients With Dry Eye Disease

Dry Eye Disease

Taiwan
Santen Pharmaceutical Co., Ltd.

Completed

A Long-term Study of DE-117 Ophthalmic Solution Monotherapy and Concomitant Use of DE-117 Ophthalmic Solution With Timolol Ophthalmic Solution in Patients With OAG or OH: RENGE Study

Open Angle Glaucoma or Ocular Hypertension

Japan
Santen Pharmaceutical Co., Ltd.

Completed

Study of DE-108 Ophthalmic Solution in Patients Who Are Scheduled for Cataract Surgery

Cataract Surgery

Korea, Republic of
Santen Pharmaceutical Co., Ltd.

Completed

DE-111 Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension

Open Angle Glaucoma or Ocular Hypertension

Japan
Santen Pharmaceutical Co., Ltd.

Completed

DE-111 Against Tafluprost Ophthalmic Solution 0.0015% Alone and Concomitant Use of Tafluprost Ophthalmic Solution 0.0015% Plus Timolol Ophthalmic Solution 0.5%

Ocular Hypertension | Open Angle Glaucoma

Japan
Santen Pharmaceutical Co., Ltd.

Completed

A Long-term Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis

Allergic Conjunctivitis

Japan
Santen Pharmaceutical Co., Ltd.

Completed

Phase III Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry Eye

Dry Eye

Japan
Santen Pharmaceutical Co., Ltd.

Completed

Late Phase II Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry Eye

Dry Eye

Japan
Santen Pharmaceutical Co., Ltd.

Completed

Efficacy and Safety of Betamethasone Microsphere in Patients With Diabetic Macular Edema (TSUBASA)

Diabetic Macular Edema

Japan
Santen Pharmaceutical Co., Ltd.

Completed

Study of DE-105 Ophthalmic Solution in Patients With Persistent Corneal Epithelial Defect

Persistent Corneal Epithelial Defect

Japan
Santen Inc.
Vistakon Pharmaceuticals

Completed

Ocular Tissue Levels of 1.5% Levofloxacin Ophthalmic Solution Compared to an Active Comparator

Cataract

United States
Mateon Therapeutics

Completed

Rollover Protocol for Subjects Who Have Responded on Study 4218s - A Phase 2 Study

Neuroendocrine Tumors

United States
Mateon Therapeutics

Terminated

FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer

Platinum Resistant Ovarian Cancer

United States, Belgium, Germany
Mateon Therapeutics

Withdrawn

Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid Cancer (FACT2)

Anaplastic Thyroid Cancer
Mateon Therapeutics

Completed

Safety and Efficacy Study of Combretastatin A4 Phosphate to Treat Patients With Choroidal Neovascularization Secondary to Pathologic Myopia

Choroidal Neovascularization | Myopia, Degenerative
Mateon Therapeutics

Completed

Safety and Effectiveness of Combretastatin A-4 Phosphate Combined With Chemotherapy in Advanced Solid Tumors

Cancer | Tumor

United States
Santen Pharmaceutical(China) Co.,LTD

Completed

A Randomized, Parallel-Group Comparison Study of Topical Corticosteroids in Dry Eye Patients With Sjögren Syndrome

Dry Eye Syndromes | Sjögren Syndrome

China
Lantern Pharma Inc.

Recruiting

A Study of LP-284 in Relapsed or Refractory Lymphomas and Solid Tumors

Advanced Solid Tumor | Relapsed or Refractory Lymphomas

United States
Lantern Pharma Inc.

Recruiting

A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma (HARMONIC)

Carcinoma, Non-Small-Cell Lung | Adenocarcinoma of Lung

United States
Pinteon Therapeutics, Inc

Completed

Safety and Tolerability of PNT001 in Healthy Adults

Healthy

United States
Mateon Therapeutics

Unknown

Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS (AML)

Myelodysplastic Syndromes | Acute Myelogenous Leukemia

United States
Mateon Therapeutics

Completed

A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers (GI-NETorPNET)

Neuroendocrine Tumors

United States
Mateon Therapeutics

Terminated

Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer (FACT)

Anaplastic Thyroid Cancer

United States, India, Belarus, Bulgaria, Egypt, Israel, Italy, Poland, Romania, Russian Federation, Ukraine, United Kingdom
Mateon Therapeutics

Completed

Safety Study of Increasing Doses of Combretastatin in Combination With Bevacizumab (Avastin) in Patients With Advanced Solid Tumors

Tumors

United Kingdom
Mateon Therapeutics

Completed

A Safety and Efficacy Study of Carboplatin, Paclitaxel, Bevacizumab and CA4P in Non-Small Cell Lung Cancer (FALCON)

Tumors

United States
Mateon Therapeutics

Completed

Study Evaluating the Safety and Response of Fosbretabulin in Asian Patients With Polypoidal Choroidal Vasculopathy (PCV)

Polypoidal Choroidal Vasculopathy

United States, Hong Kong, Korea, Republic of, Singapore, Taiwan
Mateon Therapeutics

Completed

Safety Study of Increasing Doses of Combretasatin A1 Diphosphate (OXi4503) as Monotherapy in Subjects With Hepatic Tumor Burden (OXi4503)

Neoplasm Metastasis

Australia
Santen Pharmaceutical Asia Pte. Ltd.

Recruiting

Study in Prostaglandin Associated Peri-orbitopathy Switching From Prostaglandin Monotherapy to Omidenepag Isopropyl (NOPAPS)

Ocular Hypertension | Primary Open-angle Glaucoma | Normal Tension Glaucoma | Glaucoma, Suspect

Korea, Republic of
Santen Pharmaceutical (Taiwan) Co., LTD

Completed

Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting

Primary Open Angle Glaucoma | Ocular Surface Disease

Taiwan
Santen Pharmaceutical (Taiwan) Co., LTD

Completed

Prospective, Single Center Switching Study of 0.0015% Tafluprost Ophthalmic Solution in Primary Open-angle Glaucoma and Ocular Hypertension Patients With Corneal Disorders (Switching From 0.005% Latanoprost Ophthalmic Solution)

Glaucoma, Primary Open Angle

Taiwan

3

Subscribe